NBC Securities Inc. purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 1,947 shares of the company's stock, valued at approximately $593,000.
Several other institutional investors have also made changes to their positions in the company. Sone Capital Management LLC acquired a new position in shares of Medpace during the 4th quarter worth $1,318,000. Barclays PLC increased its position in Medpace by 71.9% during the third quarter. Barclays PLC now owns 19,781 shares of the company's stock worth $6,603,000 after buying an additional 8,275 shares during the last quarter. Sanctuary Advisors LLC raised its holdings in Medpace by 20.5% during the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company's stock valued at $1,738,000 after buying an additional 844 shares in the last quarter. Truist Financial Corp raised its holdings in Medpace by 166.2% during the fourth quarter. Truist Financial Corp now owns 10,277 shares of the company's stock valued at $3,414,000 after buying an additional 6,417 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Medpace by 1.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 201,046 shares of the company's stock worth $66,794,000 after buying an additional 2,142 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Medpace
In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the transaction, the director now owns 2,998 shares in the company, valued at approximately $904,856.36. The trade was a 36.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 20.30% of the company's stock.
Analysts Set New Price Targets
A number of research analysts recently weighed in on the company. Leerink Partners started coverage on Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective on the stock. Mizuho dropped their price target on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. TD Cowen cut shares of Medpace from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $370.00 to $328.00 in a research note on Monday, April 14th. William Blair reiterated a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd. Finally, Robert W. Baird dropped their target price on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. Eleven research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Medpace currently has an average rating of "Hold" and an average price target of $349.30.
Read Our Latest Stock Report on MEDP
Medpace Stock Performance
Shares of NASDAQ:MEDP traded up $2.92 during trading on Friday, hitting $296.50. 421,400 shares of the stock were exchanged, compared to its average volume of 358,033. The company has a market capitalization of $8.52 billion, a price-to-earnings ratio of 23.48, a price-to-earnings-growth ratio of 3.81 and a beta of 1.55. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $459.77. The company's fifty day simple moving average is $298.09 and its 200-day simple moving average is $324.07.
Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The company had revenue of $558.57 million for the quarter, compared to the consensus estimate of $528.38 million. During the same period in the previous year, the business earned $3.20 earnings per share. On average, research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.
About Medpace
(
Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Featured Stories
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
